Hans Marcus Bosson
Vorstandsvorsitzender bei QUIAPEG PHARMACEUTICALS HOLDING AB
Ursprung des Netzwerks ersten Grades von Hans Marcus Bosson
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 17 | |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.
16
| Extinct | Pharmaceuticals: Major | 16 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Hans Marcus Bosson
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Biacore International AB
Biacore International AB Pharmaceuticals: MajorHealth Technology Biacore International AB offers systems that generate data on the interactions between proteins and small molecule drug candidates. Its systems are used in pharmaceutical drug discovery, antibody characterization, proteomics, immunogenicity, biotherapeutic development and manufacture and life science research applications. The company serves research centers, pharmaceutical and biotechnology companies. Biacore International markets its products in the United States, Europe, Japan and Australia. The company was founded in 1984 and is headquartered in Uppsala, Sweden | Pharmaceuticals: Major | Director/Board Member | |
HealthCap AB
HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
MEDIVIR AB | Pharmaceuticals: Major | Chairman President | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pepperdine University | College/University | Undergraduate Degree | |
University of Uppsala | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree | |
Newron Sweden AB
Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chairman Founder | |
University of Stockholm | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree Masters Business Admin | |
ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Cancer Research Technology Ltd.
Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member | |
Royal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
Henley Management College | College/University | Masters Business Admin Masters Business Admin | |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Oy Phoenix Collector Ltd.
Oy Phoenix Collector Ltd. Oil & Gas ProductionEnergy Minerals Part of Quiapeg Pharmaceuticals Holding AB, Oy Phoenix Collector Ltd. is a Finnish company that collects and recycles oil in the ports. The company is based in Hamina, Finland. Oy Phoenix Collector was acquired by Lucent Oil AB on January 31, 2008 for $0.95 million. | Oil & Gas Production | Director/Board Member Director/Board Member | |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Miscellaneous Commercial Services | Chairman Corporate Officer/Principal | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member | |
Moleculink AB
Moleculink AB Electronic Equipment/InstrumentsElectronic Technology Moleculink AB provides diagnostic products for life science research purposes. The firm provides products and services for human protein biomarker research and development. It offers analysis service for comprehensive protein biomarker analyses based on Proseek Multiplex. The company was founded by Dag Åke Ulf Landegren, Björn Lennart Ekström, Mårten Winge, Johan Erik Simon Fredriksson, Jonas Sven Peter Jarvius, Bernitz Mats Bo Johan Nilsson, and Mats Gullberg in 2004 and is headquartered in Uppsala, Sweden. | Electronic Equipment/Instruments | Founder Founder | |
Q-LINEA AB | Medical Specialties | Founder Chief Executive Officer | |
Healthcap 1999 GP AB
Healthcap 1999 GP AB Investment Banks/BrokersFinance Part of Odlander, Fredrikson & Co. AB, Healthcap 1999 GP AB is a company that manages and trades securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Director/Board Member Director/Board Member | |
Institut Supérieur de Gestion | College/University | Masters Business Admin | |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Hans von Kantzows Stiftelse | Chairman | ||
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Founder Director/Board Member Director/Board Member Director/Board Member | |
Powerfx Systems AB | Chairman Director/Board Member | ||
Javk Introduction AB | Director/Board Member | ||
F-Star Beta Ltd.
F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Rolf Lufts Stiftelse Foer Diabetesforskning | Director/Board Member | ||
Berth von Kantzows Stiftelse | Investment Trusts/Mutual Funds | Chairman | |
Kantzow Holding AB
Kantzow Holding AB Financial ConglomeratesFinance Kantzow Holding AB provides investment services. | Financial Conglomerates | Director/Board Member | |
Soundation AB
Soundation AB Packaged SoftwareTechnology Services Soundation AB develops music production software. The company is based in Stockholm, Sweden. | Packaged Software | Director/Board Member Chairman | |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Investment Managers | Consultant / Advisor | |
F-star Biotechnology Ltd.
F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member |
Statistik
International
Schweden | 29 |
Vereinigtes Königreich | 10 |
Vereinigte Staaten | 6 |
Dänemark | 3 |
Finnland | 2 |
Sektoral
Health Technology | 26 |
Consumer Services | 8 |
Finance | 7 |
Commercial Services | 4 |
Industrial Services | 2 |
Operativ
Director/Board Member | 183 |
Corporate Officer/Principal | 59 |
Chairman | 59 |
Independent Dir/Board Member | 24 |
Doctorate Degree | 13 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Hans Marcus Bosson
- Unternehmensverbindungen